Literature DB >> 22399387

Human pancreatic polypeptide in a phospholipid-based micellar formulation.

Amrita Banerjee1, Hayat Onyuksel.   

Abstract

PURPOSE: Pancreatic polypeptide (PP) has important glucoregulatory functions and thereby holds significance in the treatment of diabetes and obesity. However, short plasma half-life and aggregation propensity of PP in aqueous solution, limits its therapeutic application. To address these issues, we prepared and characterized a formulation of PP in sterically stabilized micelles (SSM) that protects and stabilizes PP in its active conformation.
METHODS: PP-SSM was prepared by incubating PP with SSM dispersion in buffer. Peptide-micelle association and freeze-drying efficacy of the formulation was characterized in phosphate buffers with or without sodium chloride using dynamic light scattering, fluorescence spectroscopy and circular dichroism. The degradation kinetics of PP-SSM in presence of proteolytic enzyme was determined using HPLC and bioactivity of the formulation was evaluated by in vitro cAMP inhibition study.
RESULTS: PP self-associated with SSM and this interaction was influenced by presence/absence of sodium chloride in the buffer. The formulation was effectively lyophilized, demonstrating feasibility for its long-term storage. The stability of peptide against proteolytic degradation was significantly improved and PP in SSM retained its bioactivity in vitro.
CONCLUSIONS: Self-association of PP with phospholipid micelles addressed the delivery issues of the peptide. This nanomedicine should be further developed for the treatment of diabetes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22399387      PMCID: PMC3349792          DOI: 10.1007/s11095-012-0718-4

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  37 in total

Review 1.  Pancreatogenic diabetes: special considerations for management.

Authors:  Yunfeng Cui; Dana K Andersen
Journal:  Pancreatology       Date:  2011-07-09       Impact factor: 3.996

Review 2.  Resistin and obesity-associated insulin resistance.

Authors:  Claire M Steppan; Mitchell A Lazar
Journal:  Trends Endocrinol Metab       Date:  2002 Jan-Feb       Impact factor: 12.015

Review 3.  Pancreatic polypeptide in pancreatitis.

Authors:  René Hennig; Panagiotis B Kekis; Helmut Friess; Thomas E Adrian; Markus W Büchler
Journal:  Peptides       Date:  2002-02       Impact factor: 3.750

4.  Characterization of the effects of pancreatic polypeptide in the regulation of energy balance.

Authors:  Akihiro Asakawa; Akio Inui; Hideki Yuzuriha; Naohiko Ueno; Goro Katsuura; Mineko Fujimiya; Masayuki A Fujino; Akira Niijima; Michael M Meguid; Masato Kasuga
Journal:  Gastroenterology       Date:  2003-05       Impact factor: 22.682

5.  In vitro characterization of PEGylated phospholipid micelles for improved drug solubilization: effects of PEG chain length and PC incorporation.

Authors:  Beena Ashok; Lise Arleth; Rex P Hjelm; Israel Rubinstein; Hayat Onyüksel
Journal:  J Pharm Sci       Date:  2004-10       Impact factor: 3.534

6.  Impaired pancreatic polypeptide release in chronic pancreatitis with steatorrhoea.

Authors:  T E Adrian; H S Besterman; C N Mallinson; C Garalotis; S R Bloom
Journal:  Gut       Date:  1979-02       Impact factor: 23.059

7.  Bovine pancreatic polypeptide (bPP) undergoes significant changes in conformation and dynamics upon binding to DPC micelles.

Authors:  Mirjam Lerch; Verena Gafner; Reto Bader; Barbara Christen; Gerd Folkers; Oliver Zerbe
Journal:  J Mol Biol       Date:  2002-10-04       Impact factor: 5.469

8.  Sterically stabilized phospholipid mixed micelles: in vitro evaluation as a novel carrier for water-insoluble drugs.

Authors:  Aparna Krishnadas; Israel Rubinstein; Hayat Onyüksel
Journal:  Pharm Res       Date:  2003-02       Impact factor: 4.200

9.  Pharmacokinetics of pancreatic polypeptide in man.

Authors:  T E Adrian; G R Greenberg; H S Besterman; S R Bloom
Journal:  Gut       Date:  1978-10       Impact factor: 23.059

Review 10.  Pancreatic polypeptide. A review.

Authors:  J Lonovics; P Devitt; L C Watson; P L Rayford; J C Thompson
Journal:  Arch Surg       Date:  1981-10
View more
  12 in total

1.  Biomarkers of Alzheimer's disease among Mexican Americans.

Authors:  Sid E O'Bryant; Guanghua Xiao; Melissa Edwards; Michael Devous; Veer Bala Gupta; Ralph Martins; Fan Zhang; Robert Barber
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 2.  When Is It Important to Measure Unbound Drug in Evaluating Nanomedicine Pharmacokinetics?

Authors:  Stephan T Stern; Marilyn N Martinez; David M Stevens
Journal:  Drug Metab Dispos       Date:  2016-09-26       Impact factor: 3.922

3.  Solubilization of therapeutic agents in micellar nanomedicines.

Authors:  Lela Vuković; Antonett Madriaga; Antonina Kuzmis; Amrita Banerjee; Alan Tang; Kevin Tao; Neil Shah; Petr Král; Hayat Onyuksel
Journal:  Langmuir       Date:  2013-12-09       Impact factor: 3.882

4.  VIP-targeted Cytotoxic Nanomedicine for Breast Cancer.

Authors:  Aparna Dagar; Antonina Kuzmis; Israel Rubinstein; Marin Sekosan; Hayat Onyuksel
Journal:  Drug Deliv Transl Res       Date:  2012-12-01       Impact factor: 4.617

5.  Novel, biocompatible, and disease modifying VIP nanomedicine for rheumatoid arthritis.

Authors:  Varun Sethi; Israel Rubinstein; Antonina Kuzmis; Helen Kastrissios; James Artwohl; Hayat Onyuksel
Journal:  Mol Pharm       Date:  2013-01-23       Impact factor: 4.939

6.  A new lipid-based nano formulation of vinorelbine.

Authors:  Fatemeh Bahadori; Gülaçtı Topçu; Mehmet S Eroğlu; Hayat Onyüksel
Journal:  AAPS PharmSciTech       Date:  2014-05-29       Impact factor: 3.246

7.  Recent developments in protein and peptide parenteral delivery approaches.

Authors:  Ashaben Patel; Kishore Cholkar; Ashim K Mitra
Journal:  Ther Deliv       Date:  2014-03

Review 8.  The future role of gut hormones in the treatment of obesity.

Authors:  Rachel C Troke; Tricia M Tan; Steve R Bloom
Journal:  Ther Adv Chronic Dis       Date:  2014-01       Impact factor: 5.091

9.  Improvement of in vivo efficacy of recombinant human erythropoietin by encapsulation in PEG-PLA micelle.

Authors:  Yanan Shi; Wan Huang; Rongcai Liang; Kaoxiang Sun; Fangxi Zhang; Wanhui Liu; Youxin Li
Journal:  Int J Nanomedicine       Date:  2012-12-27

10.  A novel peptide nanomedicine for treatment of pancreatogenic diabetes.

Authors:  Amrita Banerjee; Hayat Onyuksel
Journal:  Nanomedicine       Date:  2013-01-22       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.